12. Screening of malignant diseases: Difference between revisions

From greek.doctor
Created page with "* CRC ** Begins at age 50 ** Sigmoidoscopy ** Colonoscopy ** CT colonography (virtual colonoscopy) ** Faecal occult blood test * Breast ** Yearly mammogram after 40 ** Clinical breast exam every 3 years after 20 ** Breast self exam * Prostate ** Controversial screening *** May lead to treatment of cases which wouldn’t have been bothersome anyway ** For high-risk people *** BRCA *** Black *** History of prostate cc ** PSA ** DRE * Cervical ** 21 – 30 *** Pap smear eve..."
 
No edit summary
 
Line 28: Line 28:
** Vaccinated women should also be screened
** Vaccinated women should also be screened
** High risk screened more often
** High risk screened more often
* Lung
** People above the age of 50 with at least 20 pack-years
** Low-dose CT scan
** National screening programmes are only active in the US and China, but is under consideration in most EU countries


[[Category:Public health 5 - Detailed epidemiology]]
[[Category:Public health 5 - Detailed epidemiology]]

Latest revision as of 14:12, 18 January 2024

  • CRC
    • Begins at age 50
    • Sigmoidoscopy
    • Colonoscopy
    • CT colonography (virtual colonoscopy)
    • Faecal occult blood test
  • Breast
    • Yearly mammogram after 40
    • Clinical breast exam every 3 years after 20
    • Breast self exam
  • Prostate
    • Controversial screening
      • May lead to treatment of cases which wouldn’t have been bothersome anyway
    • For high-risk people
      • BRCA
      • Black
      • History of prostate cc
    • PSA
    • DRE
  • Cervical
    • 21 – 30
      • Pap smear every 3 years
    • 30 – 65
      • Pap smear every 5 years
      • HPV test every 5 years
    • Over 65
      • Not tested
    • Vaccinated women should also be screened
    • High risk screened more often
  • Lung
    • People above the age of 50 with at least 20 pack-years
    • Low-dose CT scan
    • National screening programmes are only active in the US and China, but is under consideration in most EU countries